Recombinant human hyaluronidase PH20 (rHuPH20)
Sponsors
Halozyme Therapeutics, ViiV Healthcare, GlaxoSmithKline
Conditions
Diabetes MellitusDiabetes Mellitus, Type 2HIV InfectionsHealthyMultiple MyelomaType 1 Diabetes Mellitus
Phase 1
Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20
CompletedNCT00705536
Start: 2007-12-31End: 2008-02-29Updated: 2019-02-26
A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone
CompletedNCT00979875
Start: 2009-09-30End: 2010-05-31Updated: 2014-07-14
Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)
CompletedNCT01275131
Start: 2011-01-31End: 2011-12-31Updated: 2014-07-25
Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants
CompletedNCT04484337
Start: 2020-07-31End: 2023-05-05Updated: 2026-05-29
A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care
Not yet recruitingNCT07742527
Start: 2026-10-16End: 2030-03-18Target: 22Updated: 2026-08-03
Phase 2
Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus
CompletedNCT00774800
Start: 2008-10-31End: 2009-03-31Updated: 2019-02-26
Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)
CompletedNCT00916357
Start: 2009-07-31End: 2009-11-30Updated: 2014-08-18